Sign In
Buy GILD
$125.16
+0.110 (+0.0880%)
At Close: Jun 24, 2026
Should Invesco S&P 500 High Dividend Low Volatility ETF (SPHD) Be on Your Investing Radar?
11:20am, Thursday, 23'rd Feb 2023 Zacks Investment Research
Style Box ETF report for SPHD
This Recession-Proof Company Has a Best-in-Class Dividend
12:30pm, Wednesday, 22'nd Feb 2023 The Motley Fool
Pfizer's highly attractive valuation, rock-solid dividend program, and enormous yield put it at the top of its big pharma peer group.
How Are Biotech ETFs Reacting to Q4 Earnings Releases?
07:21pm, Tuesday, 21'st Feb 2023 Zacks Investment Research
The latest earnings from some of the big biotech players came in at mixed this reporting season.
Gilead says its COVID-19 drug can help reduce deaths, shorten hospital stays
05:46pm, Tuesday, 21'st Feb 2023
Gilead Sciences Inc. GILD, -0.14% said Tuesday that its COVID-19 drug can help reduce deaths and readmission rates among patients hospitalized with COVID-19 and who received the drug, remdesivir, shor
How Are Biotech ETFs Reacting to Q4 Earnings Releases?
03:48pm, Tuesday, 21'st Feb 2023
The latest earnings from some of the big biotech players came in at mixed this reporting season.
Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now?
11:20am, Tuesday, 21'st Feb 2023 Zacks Investment Research
Smart Beta ETF report for DIV
Gilead (GILD) Reports Positive Data From Urothelial Cancer Study
04:53pm, Monday, 20'th Feb 2023 Zacks Investment Research
Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.
Gilead (GILD) Reports Positive Data From Urothelial Cancer Study
01:32pm, Monday, 20'th Feb 2023
Gilead's (GILD) new and updated positive results from a phase II study show Trodelvy's rapid and durable responses for patients across a range of hard-to-treat types of mUC.
Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?
11:20am, Monday, 20'th Feb 2023 Zacks Investment Research
Style Box ETF report for SPYD
The Zacks Analyst Blog Highlights Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences
04:39pm, Friday, 17'th Feb 2023 Zacks Investment Research
Tesla, Eli Lilly, Bank of America, QUALCOMM and Gilead Sciences are part of the Zacks top Analyst Blog.
Top Analyst Reports for Tesla, Eli Lilly & Bank of America
04:00pm, Thursday, 16'th Feb 2023 Zacks Investment Research
Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), Eli Lilly and Company (LLY) and Bank of America Corporation (BAC).
5 Least-Hurt Biotech ETFs of the Last Week
06:00pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
5 Least-Hurt Biotech ETFs of the Last Week
02:18pm, Wednesday, 15'th Feb 2023
Rising rate worries have weighed on the biotech sector. However, these biotech ETFs still have lost the least in recent days.
Gilead Sciences, Inc. (GILD) SVB Securities Global Biopharma Conference (Transcript)
03:41pm, Tuesday, 14'th Feb 2023
Gilead Sciences, Inc. (NASDAQ:GILD ) SVB Securities Global Biopharma Conference February 14, 2023 11:20 AM ET Company Participants Merdad Parsey - Chief Medical Officer Conference Call Participants Da
Lattice Semiconductor To Rally 33%? Here Are 10 Other Analyst Forecasts For Tuesday
12:30pm, Tuesday, 14'th Feb 2023 Benzinga
Goldman Sachs boosted the price target for Kaiser Aluminum Corporation (NASDAQ: KALU) from $70 to $80. Goldman Sachs analyst Emily Chieng maintained a Sell rating on the stock. Kaiser Aluminum share
